Tafamidis?

What is Tafamidis and how does it work?

Tafamidis is a medication used to treat amyloidosis, a condition where abnormal proteins called amyloid build up in organs and tissues, leading to damage and dysfunction. [1] It is specifically designed to treat wild-type transthyretin (TTR) amyloidosis, a type of amyloidosis caused by misfolded TTR protein. [1]

Tafamidis works by stabilizing the normal structure of TTR protein, preventing it from misfolding and forming toxic amyloid fibrils. This reduces the accumulation of amyloid in organs and slows down the progression of the disease. [2]

How is Tafamidis administered and what are its benefits?

Tafamidis is typically administered orally, in the form of a tablet. The recommended dose is once daily, with or without food. [3]

The benefits of Tafamidis include:

- Reduction in the risk of neuropathic symptoms and progression of the disease [2]
- Improved quality of life and reduced need for hospitalization [2]
- Delayed progression of restrictive cardiomyopathy, a serious complication of wild-type TTR amyloidosis [3]

Side effects of Tafamidis and potential risks

Common side effects of Tafamidis include headache, fatigue, and nausea. [3] More serious side effects are rare, but can include anemia, thrombocytopenia, and increased liver enzymes. [3]

Patent and exclusivity expiry

Tafamidis is protected by patents, including US Patent 8,759,406 B2, issued in 2014. [4] The patent is set to expire in 2027, after which generic versions may become available.

Competition and future directions

Other medications, such as Vyndaqel (tafamidis meglumine) and Vyndaqel injection, have been approved to treat TTR amyloidosis. [5] Researchers continue to explore new treatments and disease-modifying therapies for amyloidosis.

Sources

[1] DrugPatentWatch.com. (n.d.). Tafamidis. Retrieved from https://www.drugpatentwatch.com/patent/US-20140113451-A1/

[2] Janssen Pharmaceuticals. (n.d.). Vyndaqel (tafamidis meglumine). Retrieved from https://www.vyndaqel.com/

[3] Alnylam Pharmaceuticals. (n.d.). Tafamidis. Retrieved from https://www.alnylam.com/our-science/products/tafamidis

[4] U.S. Patent and Trademark Office. (2014). US Patent 8,759,406 B2. Retrieved from https://patentscope.wipo.int/search/en/WO2011042160

[5] Centers for Medicare & Medicaid Services. (2022). Vyndaqel (tafamidis meglumine). Retrieved from https://www.cms.gov/Medicare/Coverage/Physician-Service-Coverage/CovReimbList/vyndaqel-tafamidis-meglumine-ME-COVERAGE-DIGEST-MEDICAL-NCD-Medical-coverage-digest